Vassilis Genoud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vassilis Genoud has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Thibaud Koessler
Oncology Department, Geneva University Hospitals , Geneva 1205
2 shared publications- Alfredo Addeo
Oncology Department, University Hospital Geneva, Geneva, Switzerland
1 shared publication Aurélie Bornand
Pathology Department, Geneva University Hospital, Geneva, Switzerland
1 shared publicationClaudia Corro
Oncology Department, Geneva University Hospital, Geneva, Switzerland
1 shared publication- Maxime Borgeaud
Oncology Department, Geneva University Hospitals, 1205 Geneva, Switzerland
1 shared publication - Mihaela Aldea
Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (12)
Targeting the MTAP-PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities
Homozygous deletion of methylthioadenosine phosphorylase (MTAP), one of the most frequent somatic copy-number alterations in cancer, creates a context of synthetic lethal vulnerability. MTAP loss leads to the accumulation of 5'-methylthioadenosine (MTA), which partly inhibits protein arginine methyltransferase 5 (PRMT5), and induces a dependency on residual PRMT5 activity; a dependency that can be pharmacologically exploited. This review describes the MTAP-PRMT5 synthetic lethal axis from molecular biology to clinical translation. First-generation nonselective PRMT5 inhibitors were limited by hematological toxicity and reduced potency in MTA-rich environments. Second-generation MTA-cooperative inhibitors, which overcome these constraints by selectively stabilizing the inactive PRMT5-MTA complex, are characterized by tumor selectivity. Early-phase clinical data for MTA cooperative PRMT5 inhibitors showed encouraging signals of efficacy with manageable safety profiles in early-phase trials, establishing clinical proof of concept. Various agents have now entered the next steps of clinical development either alone or in combination. In this review we also discuss the biomarker challenges, essential to patient selection, including the limitations of different methods, as well as emerging resistance mechanisms to PRMT5 inhibitors. Molecular testing standardization, pharmacodynamic endpoint integration, and prospective resistance characterization are identified as priorities for next phases of development of PRMT5 inhibition.
- 22 October 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (12)
Open AccessTargeting the MTAP-PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities
Homozygous deletion of methylthioadenosine phosphorylase (MTAP), one of the most frequent somatic copy-number alterations in cancer, creates a context of synthetic lethal vulnerability. MTAP loss leads to the accumulation of 5'-methylthioadenosine (MTA), which partly inhibits protein arginine methyltransferase 5 (PRMT5), and induces a dependency on residual PRMT5 activity; a dependency that can be pharmacologically exploited. This review describes the MTAP-PRMT5 synthetic lethal axis from molecular biology to clinical translation. First-generation nonselective PRMT5 inhibitors were limited by hematological toxicity and reduced potency in MTA-rich environments. Second-generation MTA-cooperative inhibitors, which overcome these constraints by selectively stabilizing the inactive PRMT5-MTA complex, are characterized by tumor selectivity. Early-phase clinical data for MTA cooperative PRMT5 inhibitors showed encouraging signals of efficacy with manageable safety profiles in early-phase trials, establishing clinical proof of concept. Various agents have now entered the next steps of clinical development either alone or in combination. In this review we also discuss the biomarker challenges, essential to patient selection, including the limitations of different methods, as well as emerging resistance mechanisms to PRMT5 inhibitors. Molecular testing standardization, pharmacodynamic endpoint integration, and prospective resistance characterization are identified as priorities for next phases of development of PRMT5 inhibition.
- Open Access
- 27 November 2025
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 12 (1) , e001925
Actionable mutations in pancreatic cancer: where targeted therapies are making a difference
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid tumours, with 5-year survival consistently below 10% and only modest gains from conventional chemotherapy after first-line failure. Although oncogenic KRAS mutations dominate the genomic landscape, recent large-scale sequencing has revealed a series of less frequent but therapeutically actionable alterations. This review synthesises evidence from phase I–II trials published through April 2025. It demonstrates that targeting these lesions can yield outcomes that meet or exceed the benchmarks set by the NAPOLI-1 trial (liposomal irinotecan plus 5-fluorouracil and leucovorin), with a median overall survival of 6.2 months and progression-free survival of 3.1 months. Objective response rates reach 33% with adagrasib in KRAS G12C PDAC, 22% with olaparib maintenance in germline BRCA1/2 cancers, and over 50% with RET or NTRK inhibitors with fusion alterations; pembrolizumab produces durable benefit in the 1–3% of tumours that are MSI-H/dMMR. Emerging data highlight NRG1 fusions (overall response rate 42% with zenocutuzumab), HER2 amplification, MTAP deletion with PRMT5 dependency and variant-specific (MRTX1133) or pan-RAS (daraxonrasib) inhibitors as the next frontier. Toxicity profiles of targeted agents are generally favourable and often allow prolonged administration compared with cytotoxic regimens. Taken together, these advances represent a substantive therapeutic progress in PDAC over the past decades, even though they currently apply to a minority of patients. These findings underscore the necessity of comprehensive next-generation sequencing for every patient with advanced disease, enabling identification of rare, yet clinically meaningful, targets and moving PDAC management towards a precision-oncology paradigm.
- 27 November 2025
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 12 (1) , e001925
Open AccessActionable mutations in pancreatic cancer: where targeted therapies are making a difference
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid tumours, with 5-year survival consistently below 10% and only modest gains from conventional chemotherapy after first-line failure. Although oncogenic KRAS mutations dominate the genomic landscape, recent large-scale sequencing has revealed a series of less frequent but therapeutically actionable alterations. This review synthesises evidence from phase I–II trials published through April 2025. It demonstrates that targeting these lesions can yield outcomes that meet or exceed the benchmarks set by the NAPOLI-1 trial (liposomal irinotecan plus 5-fluorouracil and leucovorin), with a median overall survival of 6.2 months and progression-free survival of 3.1 months. Objective response rates reach 33% with adagrasib in KRAS G12C PDAC, 22% with olaparib maintenance in germline BRCA1/2 cancers, and over 50% with RET or NTRK inhibitors with fusion alterations; pembrolizumab produces durable benefit in the 1–3% of tumours that are MSI-H/dMMR. Emerging data highlight NRG1 fusions (overall response rate 42% with zenocutuzumab), HER2 amplification, MTAP deletion with PRMT5 dependency and variant-specific (MRTX1133) or pan-RAS (daraxonrasib) inhibitors as the next frontier. Toxicity profiles of targeted agents are generally favourable and often allow prolonged administration compared with cytotoxic regimens. Taken together, these advances represent a substantive therapeutic progress in PDAC over the past decades, even though they currently apply to a minority of patients. These findings underscore the necessity of comprehensive next-generation sequencing for every patient with advanced disease, enabling identification of rare, yet clinically meaningful, targets and moving PDAC management towards a precision-oncology paradigm.